British developed a new drug for the treatment of leukemia I-BET151

Researchers at Cambridge University and other institutions in the United Kingdom reported that they have developed a new drug for the treatment of mixed leukemia. Animal experiments and experiments on human cells in vitro have shown that the drug is effective.

Mixed leukemia is caused by mutations in the gene called MLL, and the mutated gene will direct the production of a "fusion protein," which in turn affects other genes, eventually triggering leukemia. In this disease chain, the researchers found that one can intervene in that the fusion protein needs the help of a protein code-named BET to affect other genes.

Researchers at institutions such as the University of Cambridge in the United Kingdom reported on the website of Nature magazine in the United Kingdom that they had found a chemical that could block the function of the BET protein. Experiments have shown that this substance called I-BET151 can effectively treat the mixed mouse leukemia that the experimental mice suffer from, and it also has a therapeutic effect on human diseased cells cultured in vitro.

Researcher Brian Huntley said that mixed leukemia is difficult to treat, and patients often need bone marrow transplants to survive. It is hoped that the results of this study can help patients get rid of their dependence on bone marrow transplantation in the future.

Covid-19 Rapid Test

covid-19 rapid test saliva test antigen test

covid rapid test antigen saliva

Shaoxing Aladdin Enterprise Co.,Ltd , https://www.xhemostat.com